Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
AFDX-384 is a drug targeting M2 and M4 muscarinic receptors, and is used for mapping receptor distribution in the brain. Muscarinic acetylcholine receptors (mAChRs) are GPCRs that play a role in the parasympathetic nervous system. Muscarinic acetylcholine receptors are potential targets for dementia and schizophrenia.
We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (Bmax), dissociation constants (Kd), association and dissociation rates (kon and koff), and inhibitor constants (Ki) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.
Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, PerkinElmer has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.
References for NET1041:
|Label Position||Specifically Labeled|
|Product Brand Name||NEN Radiochemicals|
|Receptor Type||Acetylcholine (Muscarinic)|
|Shipping Condition||Dry Ice|
|Special Ordering Information||This is a radioactive product - shipping address must have a license to receive radioactive materials.|
|Therapeutic Area||CNS & Neurologic, Cardiovascular, Gastrointestinal|
|Unit Size||250 µCi|
For over 50 years PerkinElmer has been a leading supplier of radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. Today is no different. We have always been committed to providing you products for all of your radiometric needs and we are still committed today.